Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia

Table 1 Demographic and epidemiologic parameters of the probability of developing pneumococcal disease and the efficacy of PCV13 and PCV10 and cost of care in Colombian children younger than 5 years, 2014

Parameters		Mean value		Data distribution	Reference
Demographic
Newborns in 2012		676 835		Does not vary	[19]
Life expectancy		73,78		Does not vary	[9]
Discount rate		3%		2% - 5%	[13]
Epidemiologic
Pneumococcal sepsis probability		0,000184		Beta	[13]
Pneumococcal meningitis probability		0,000037		Beta	[13]
Radiographically confirmed pneumonia probability (a)		0,007441		Beta	[13,15]
Pneumococcal AOM probability (b)		0,031171		Beta	[15,17]
PID mortality (meningitis, sepsis)		37%		Beta	[18]
Pneumonia mortality		3%		Beta	[18]
Vaccination coverage		90%		Beta	Assumption
Herd effect		42%			[20]
Parameter	Mean value	Range		Data distribution	References
Parameter	Mean value	Inferior limit	Superior limit	Data distribution	References
Efficacy of intervention
Meningitis, sepsis PCV10	65,0%	11,1%	86,2%	Beta	[22]
Radiographically confirmed pneumonia PCV10	22,4%	5,7%	36,1%	Beta	[22]
AOM due to S. pneumoniae PCV10 (c)	32,4%	21,6%	40,4%	Beta	[11,16]
Meningitis, sepsis PCV13	89,1%	73,7%	95,6%	Beta	[5]
Radiographically confirmed pneumonia PCV13	30,3%	10,7%	45,7%	Beta	[21]
AOM due to S. pneumoniae PCV13 (d)	68,1%	61,5%	74,6%	Beta	[11,23]
Vaccine costs
Cost of PCV10	$ 14,12	$ 12,71	$ 15,53	Gama	[24]
Cost of PCV13	$ 15,68	$ 14,11	$ 17,25	Gama	[24]
Administration cost (per dose)	$ 1,00	$ 0,9	$ 1,10	Gama	Assumption
Cost of sepsis	$ 8 192	$292	$ 104 535	Gama	Health insurance company
Cost of meningitis	$11 595	$ 1 165	$ 54 891	Gama	Health insurance company
Cost of pneumonia	$ 1 854	$ 306	$ 40 812	Gama	Health insurance company
Cost of AOM	$ 40	$ 36	$ 44	Gama	[26,27]

a. Incidence of pneumonia in Medellin in 2009, adjusted to the proportion of pneumonia cases confirmed radiographically (Benavides et al [13]).
b. Incidence of AOM in Medellin in 2009, adjusted to the proportion of AOM cases due to pneumococcus (Sierra et al [17]).
c. Clinical efficacy of PCV11 for preventing AOM due to S. pneumoniae, adjusted according to the proportional frequency of serotypes circulating in Colombia between 2009 and 2012, contained in PCV10.
d. Clinical efficacy of PCV7 for preventing AOM due to S. pneumoniae, adjusted according to the proportional frequency of serotypes circulating in Colombia between 2009 and 2012, contained in PCV13.

ISSN: 1478-7547